VOR Vor Biopharma

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.

Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1

Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the Company’s website at:

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:

Carl Mauch

Sarah Spencer



EN
12/09/2025

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Infla...

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company’s we...

September 12, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. “We are delighted to welcome Adi to Vor...

September 2, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for I...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults wi...

August 27, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School ConferenceFireside Chat: Tuesday, September 2nd, 2025, at 11:15am ETLocation: Boston, MA A live webcast and archived replay of the fireside chat will be available on the investors section of . Baird 2025 Global Healthcare Conference 1x1 Investor...

August 26, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio’s common stock to seven newly hi...

August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch